Recent Company News

• 07:06 AM ET Apr 28, 2025
  

  RedHill Biopharma secures allowance of Chinese patent application for RHB-107 ($2.41, 0.00)

• 07:04 AM ET Apr 28, 2025
  

  RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

• 04:01 PM ET Apr 17, 2025
  

  RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

• 07:03 AM ET Apr 16, 2025
  

  RedHill Biopharma announced the new publication of in vivo data, in the journal Diabetes, Metabolic Syndrome and Obesity ($2.14, 0.00)

• 07:00 AM ET Apr 16, 2025
  

  RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

• 07:51 AM ET Apr 10, 2025
  

  RedHill Biopharma reports FY net income ($8.3M) vs year-ago $23.9M ($2.70, 0.00)

• 07:48 AM ET Apr 10, 2025
  

  RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

• 07:01 AM ET Mar 18, 2025
  

  RedHill Biopharma to submit FDA-approved Talicia for UK marketing authorisation ($3.01, 0.00)

• 07:00 AM ET Mar 18, 2025
  

  RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

• 07:11 AM ET Mar 12, 2025
  

  RedHill plans to initiate Phase 2 study of RHB-204 in Mycobacterium avium subspecies paratuberculosis-positive (MAP+) moderate to severe CD ($2.79, 0.00)